Targeting the T-cell membrane type-1 matrix metalloproteinase-CD44 axis in a transferred type 1 diabetes model in NOD mice.
Savinov AY, Strongin AY.
Exp Ther Med · research-article; journal article · DOI 10.3892/etm.2012.821 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för prinomastat. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
14 träffarCrystal structure of human cytochrome P450 2D6 with prinomastat bound.
Wang A, Savas U, Hsu MH, Stout CD, Johnson EF.
J Biol Chem · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1074/jbc.m111.307918Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma.
Heath EI, Burtness BA, Kleinberg L, Salem RR, Yang SC, Heitmiller RF, Canto MI, Knisely JP, Topazian M, Montgomery E, Tsottles N, Pithavala Y, Rohmiller B, Collier M, Forastiere AA.
Invest New Drugs · clinical trial, phase ii; clinical trial; randomized controlled trial; journal article · DOI 10.1007/s10637-006-5934-5Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer.
Bissett D, O'Byrne KJ, von Pawel J, Gatzemeier U, Price A, Nicolson M, Mercier R, Mazabel E, Penning C, Zhang MH, Collier MA, Shepherd FA.
J Clin Oncol · clinical trial, phase iii; clinical trial; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1200/jco.2005.03.170The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinase, on a new animal model of epiretinal membrane.
El-Bradey MH, Cheng L, Bartsch DU, Niessman M, El-Musharaf A, Freeman WR.
Retina · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; journal article · DOI 10.1097/00006982-200410000-00016Preventive versus treatment effect of AG3340, a potent matrix metalloproteinase inhibitor in a rat model of choroidal neovascularization.
El Bradey M, Cheng L, Bartsch DU, Appelt K, Rodanant N, Bergeron-Lynn G, Freeman WR.
J Ocul Pharmacol Ther · comparative study; research-article; journal article · DOI 10.1089/1080768041223657Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor.
Hande KR, Collier M, Paradiso L, Stuart-Smith J, Dixon M, Clendeninn N, Yeun G, Alberti D, Binger K, Wilding G.
Clin Cancer Res · clinical trial; research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-0981-3The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on uveal melanoma rabbit model.
Ozerdem U, Mach-Hofacre B, Varki N, Folberg R, Mueller AJ, Ochabski R, Pham T, Appelt K, Freeman WR.
Curr Eye Res · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; journal article · DOI 10.1076/ceyr.24.2.86.8159Efficacy of Prinomastat) (AG3340), a matrix metalloprotease inhibitor, in treatment of retinal neovascularization.
Garcia C, Bartsch DU, Rivero ME, Hagedorn M, McDermott CD, Bergeron-Lynn G, Cheng L, Appelt K, Freeman WR.
Curr Eye Res · journal article · DOI 10.1076/ceyr.24.1.33.5429Ventilator-induced lung injury upregulates and activates gelatinases and EMMPRIN: attenuation by the synthetic matrix metalloproteinase inhibitor, Prinomastat (AG3340).
Foda HD, Rollo EE, Drews M, Conner C, Appelt K, Shalinsky DR, Zucker S.
Am J Respir Cell Mol Biol · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1165/ajrcmb.25.6.4558fEvaluation of intraocular pharmacokinetics and toxicity of prinomastat (AG3340) in the rabbit.
Cheng L, Rivero ME, Garcia CR, McDermott CD, Keefe KS, Wiley CA, Soules KA, Bergeron-Lynn G, Vekich S, Zhang K, Appelt K, Freeman WR.
J Ocul Pharmacol Ther · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; journal article · DOI 10.1089/108076801750295326The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on posttraumatic proliferative vitreoretinopathy.
Ozerdem U, Mach-Hofacre B, Keefe K, Pham T, Soules K, Appelt K, Freeman WR.
Ophthalmic Res · comparative study; research support, u.s. gov't, p.h.s.; journal article · DOI 10.1159/000055636The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy.
Ozerdem U, Mach-Hofacre B, Cheng L, Chaidhawangul S, Keefe K, McDermott CD, Bergeron-Lynn G, Appelt K, Freeman WR.
Curr Eye Res · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; journal article · DOI 10.1076/0271-3683(200006)2061-yft447AG-3340 (Agouron Pharmaceuticals Inc).
Griffioen AW.
IDrugs · journal article